The present invention relates to combinations of lasmiditan and a calcitonin gene-related peptide (CGRP) antagonist, for example the combination of lasmiditan and galcanezumab, and to methods of using the combinations for treatment of migraine, particularly migraine inadequately controlled by lasmiditan or a CGRP antagonist therapy alone, and more particularly, to treat therapy resistant migraine which is defined herein as migraine refractory to two or more prior monotherapy and/or dual therapy treatment regimens.本發明係關於拉米迪坦(lasmiditan)及降血鈣素基因相關肽(CGRP)拮抗劑之組合，例如拉米迪坦及伽奈珠單抗(galcanezumab)之組合，且關於使用該等組合治療偏頭痛、特別是單獨拉米迪坦或CGRP拮抗劑療法無法適當控制之偏頭痛的方法，且更特定言之，關於治療抗療法偏頭痛，該抗療法偏頭痛在本文中定義為難以用兩種或兩種以上先前單藥療法及/或雙重療法治療方案治療的偏頭痛。
